将戒烟服务融入多学科肺癌治疗中：基本原理、现状和未来方向。
Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions.
机构信息
1 Department of Cell and Molecular Pharmacology and Experimental Therapeutics and Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA ; 2 Division of Social and Behavioral Sciences, School of Public Health, University of Memphis, Memphis, TN, USA.
出版信息
Transl Lung Cancer Res. 2015 Aug;4(4):339-52. doi: 10.3978/j.issn.2218-6751.2015.07.15.
Abstract
Tobacco use is the largest risk factor for lung cancer and many lung cancer patients still smoke at the time of diagnosis. Although clinical practice guidelines recommend that all patients receive evidence-based tobacco treatment, implementation of these services in oncology practices is inconsistent and inadequate. Multidisciplinary lung cancer treatment programs offer an ideal environment to optimally deliver effective smoking cessation services. This article reviews best practice recommendations and current status of tobacco treatment for oncology patients, and provides recommendations to optimize delivery of tobacco treatment in multidisciplinary practice.
摘要
吸烟是导致肺癌的最大风险因素，许多肺癌患者在确诊时仍在吸烟。尽管临床实践指南建议所有患者都接受基于证据的烟草治疗，但这些服务在肿瘤学实践中的实施情况并不一致且不足。多学科肺癌治疗计划为最佳提供有效的戒烟服务提供了理想的环境。本文回顾了肿瘤患者的烟草治疗最佳实践建议和现状，并提供了优化多学科实践中烟草治疗实施的建议。
相似文献
1
Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions.
Transl Lung Cancer Res. 2015 Aug;4(4):339-52. doi: 10.3978/j.issn.2218-6751.2015.07.15.
2
Tobacco Use Assessment and Treatment in Cancer Patients: A Scoping Review of Oncology Care Clinician Adherence to Clinical Practice Guidelines in the U.S.
Oncologist. 2019 Feb;24(2):229-238. doi: 10.1634/theoncologist.2018-0246. Epub 2018 Nov 16.
3
Readiness of Lung Cancer Screening Sites to Deliver Smoking Cessation Treatment: Current Practices, Organizational Priority, and Perceived Barriers.
Nicotine Tob Res. 2016 May;18(5):1067-75. doi: 10.1093/ntr/ntv177. Epub 2015 Sep 7.
4
Tobacco treatment implementation within 28 commission on cancer accredited programs in the Northeast region of the USA: A pilot study.
Transl Behav Med. 2018 Sep 8;8(5):706-713. doi: 10.1093/tbm/ibx024.
5
Contemporary perspectives in tobacco cessation: what oncologists need to know.
Oncologist. 2001;6(6):496-505. doi: 10.1634/theoncologist.6-6-496.
6
Treatment of tobacco use in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Chest. 2013 May;143(5 Suppl):e61S-e77S. doi: 10.1378/chest.12-2349.
7
A Sustainable Smoking Cessation Program for Patients With Lung Cancer.
Clin J Oncol Nurs. 2016 Aug 1;20(4):E106-11. doi: 10.1188/16.CJON.E106-E111.
8
State-of-the-art office-based interventions to eliminate youth tobacco use: the past decade.
Pediatrics. 2015 Apr;135(4):734-47. doi: 10.1542/peds.2014-2037. Epub 2015 Mar 16.
9
10
Babies Living Safe & Smokefree: randomized controlled trial of a multilevel multimodal behavioral intervention to reduce low-income children's tobacco smoke exposure.
BMC Public Health. 2017 Mar 14;17(1):249. doi: 10.1186/s12889-017-4145-7.
引用本文的文献
1
Perspectives on smoking cessation in the oncology environment: insights from brazilian patients and healthcare providers.
Rev Bras Epidemiol. 2025 Aug 8;28:e250046. doi: 10.1590/1980-549720250046. eCollection 2025.
2
The Best Supportive Care in Stage III Non-Small-Cell Lung Cancer.
Curr Oncol. 2023 Dec 29;31(1):183-202. doi: 10.3390/curroncol31010012.
3
Smoking Cessation Training and Treatment: Options for Cancer Centres.
Curr Oncol. 2022 Mar 24;29(4):2252-2262. doi: 10.3390/curroncol29040183.
4
Cancer care clinicians' provision of smoking cessation support: A mixed methods study in New South Wales, Australia.
Asia Pac J Clin Oncol. 2022 Dec;18(6):723-734. doi: 10.1111/ajco.13769. Epub 2022 Mar 31.
5
Interest in Cessation Treatment Among People Who Smoke in a Community-Based Multidisciplinary Thoracic Oncology Program.
JTO Clin Res Rep. 2021 May 7;2(6):100182. doi: 10.1016/j.jtocrr.2021.100182. eCollection 2021 Jun.
6
Smoking Cessation in Cancer Survivors.
Korean J Fam Med. 2021 Jul;42(4):258-259. doi: 10.4082/kjfm.42.4E. Epub 2021 Jul 20.
7
Mixed-methods economic evaluation of the implementation of tobacco treatment programs in National Cancer Institute-designated cancer centers.
Implement Sci Commun. 2021 Apr 9;2(1):41. doi: 10.1186/s43058-021-00144-7.
8
Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer.
PLoS One. 2020 Oct 8;15(10):e0236503. doi: 10.1371/journal.pone.0236503. eCollection 2020.
9
Pragmatic Application of the RE-AIM Framework to Evaluate the Implementation of Tobacco Cessation Programs Within NCI-Designated Cancer Centers.
Front Public Health. 2020 Jun 12;8:221. doi: 10.3389/fpubh.2020.00221. eCollection 2020.
10
Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control.
J Cancer Surviv. 2020 Feb;14(1):53-58. doi: 10.1007/s11764-019-00826-1. Epub 2019 Nov 4.
本文引用的文献
1
Integrating tobacco treatment into thoracic oncology settings: Lessons learned.
J Health Psychol. 2016 Dec;21(12):2813-2823. doi: 10.1177/1359105315587136. Epub 2015 Jun 4.
2
Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival.
Radiother Oncol. 2015 May;115(2):257-63. doi: 10.1016/j.radonc.2015.04.010. Epub 2015 May 23.
3
Combating acquired resistance to tyrosine kinase inhibitors in lung cancer.
Am Soc Clin Oncol Educ Book. 2015:e165-73. doi: 10.14694/EdBook_AM.2015.35.e165.
4
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.
J Thorac Dis. 2015 Mar;7(3):462-70. doi: 10.3978/j.issn.2072-1439.2015.02.13.
5
Does a Recent Cancer Diagnosis Predict Smoking Cessation? An Analysis From a Large Prospective US Cohort.
J Clin Oncol. 2015 May 20;33(15):1647-52. doi: 10.1200/JCO.2014.58.3088. Epub 2015 Apr 20.
6
A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736.
Transl Lung Cancer Res. 2014 Dec;3(6):408-10. doi: 10.3978/j.issn.2218-6751.2014.11.10.
7
Lung cancer screening guidelines: common ground and differences.
Transl Lung Cancer Res. 2014 Jun;3(3):131-8. doi: 10.3978/j.issn.2218-6751.2014.06.12.
8
Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology.
J Clin Oncol. 2015 Mar 10;33(8):952-63. doi: 10.1200/JCO.2014.59.4465. Epub 2015 Jan 8.
9
Efficacy of a tobacco quitline among adult cancer survivors.
Prev Med. 2015 Apr;73:22-7. doi: 10.1016/j.ypmed.2014.12.019. Epub 2015 Jan 5.
10
Cancer statistics, 2015.
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
Zotero 插件